Loading...

MRUS MERUS NV Investments/Divestments 8-K Filing

MRS

MRS

MERUS NV

(MRUS)

2024 8-K

Show Summary

Summary

Equity Offerings

Product Expansion

License Agreement

FDA Deadline Extended

Appointment of Chief Medica...

Underwriting Agreement

Clinical Development Update

Amendment to Voting Results

Annual Meeting Approval

Collaboration Agreement wit...

Public Offering

Appointment of CFO

Annual General Meeting

Termination of Open Market ...

Clinical Development Updates

Financial Updates

Appointment of Peter B. Sil...

External Links:

Merus N.V. provided updates on the clinical development of petosemtamab, including interim clinical data from a Phase 1/2 trial for the treatment of head and neck squamous cell carcinoma.

AI Assistant

MERUS NV

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.